why choose us

First received: August 29, 2022

Clinical Trial: Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Gynecologic Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase Ib/II Single Arm Study of Cabozantinib Plus Dostarlimab in Women With Recurrent Gynecologic Carcinosarcoma

Brief Summary: Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in gynecological cancers has been disappointing.Pre-clinical evidence supports the combination of using Vascular Endothelial Growth Factors (VEGF) inhibitors with immunotherapy.VEGF inhibitors suppress the activation of tumor-associated macrophages (TAMs) and VEGF has been shown to affect the functional maturation of dendritic cells; therefore, VEGF inhibitors could improve the function of antigen…

Read more